Kala Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Kala Pharmaceuticals
KALA Stock  USD 7.00  0.45  6.87%   
Kala Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Kala Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Kala Pharmaceuticals financial statements helps investors assess Kala Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Kala Pharmaceuticals' valuation are summarized below:
Gross Profit
1.3 M
Market Capitalization
39.9 M
Enterprise Value Revenue
0.0421
Earnings Share
(11.67)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental ratios for Kala Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Kala Pharmaceuticals last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of March 18, 2025, Market Cap is expected to decline to about 63.4 M. In addition to that, Enterprise Value is expected to decline to about 33.3 M

Kala Pharmaceuticals Total Revenue

3.89 Million

Check Kala Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kala Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 4.9 M, Selling General Administrative of 44 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 16.28, Dividend Yield of 0.0 or PTB Ratio of 2.48. Kala financial statements analysis is a perfect complement when working with Kala Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kala Pharmaceuticals Correlation against competitors.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

Kala Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets116.8 M64.3 M80.6 M
Slightly volatile
Total Current Liabilities18 M9.6 M12.7 M
Slightly volatile
Other Liabilities5.1 M4.9 M3 M
Slightly volatile
Accounts Payable1 M1.1 M1.5 M
Slightly volatile
Cash79.6 M58.5 M56.5 M
Slightly volatile
Other Assets504.7 K531.3 K5.6 M
Pretty Stable
Long Term Debt43.8 M39.3 M31.3 M
Slightly volatile
Net Receivables257.8 K271.4 K3.2 M
Slightly volatile
Common Stock Shares Outstanding2.9 M2.8 M1.2 M
Slightly volatile
Other Current Assets2.5 M2 M1.7 M
Slightly volatile
Total Liabilities91.9 M55.7 M63.5 M
Slightly volatile
Short and Long Term Debt3.5 M5.8 M4.2 M
Pretty Stable
Total Current Assets98.6 M60.8 M68.7 M
Slightly volatile
Short Term Debt285.6 K300.6 K2.8 M
Slightly volatile
Common Stock3.3 K3.5 K16.2 K
Pretty Stable
Property Plant Equipment454.5 K478.4 K5.4 M
Pretty Stable
Short and Long Term Debt Total61 M41.8 M40.7 M
Slightly volatile
Other Current Liabilities6.6 M6.9 M8.7 M
Slightly volatile
Property Plant And Equipment Net3 M3.2 M7.2 M
Pretty Stable
Non Current Assets Total3.4 M3.5 M11 M
Pretty Stable
Non Currrent Assets Other328.8 K346.1 K2.1 M
Pretty Stable
Cash And Short Term Investments96.5 M58.5 M60.8 M
Slightly volatile
Common Stock Total Equity71.2 K67.8 K29.8 K
Slightly volatile
Long Term Debt Total44.5 M83.1 M39.1 M
Slightly volatile
Liabilities And Stockholders Equity128.3 M64.3 M80.3 M
Slightly volatile
Non Current Liabilities Total59.2 M36.1 M66.2 M
Very volatile
Capital Surpluse603.4 M574.7 M253.1 M
Slightly volatile
Other Stockholder Equity373.2 M732.4 M261 M
Slightly volatile
Property Plant And Equipment Gross4.2 M4.5 M7.6 M
Pretty Stable
Non Current Liabilities Other3.5 M3.7 M6.6 M
Slightly volatile
Net Invested Capital35.6 M37.5 M99.2 M
Slightly volatile
Net Working Capital78 M40.1 M94.1 M
Slightly volatile
Capital Lease Obligations1.8 M1.9 M20.5 M
Slightly volatile
Capital Stock2.6 K2.7 K29.8 K
Slightly volatile
Current Deferred Revenue919.1 K967.5 K21.4 M
Slightly volatile

Kala Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative44 M25 M30.3 M
Slightly volatile
Research Development21.9 M21.4 M18 M
Slightly volatile
Total Operating Expenses66.1 M44.7 M48.9 M
Slightly volatile
Interest Income3 M2.8 M1.2 M
Slightly volatile
Depreciation And Amortization331 K348.4 K801.4 K
Slightly volatile
Other Operating Expenses72.7 M45 M49.6 M
Slightly volatile
Non Recurring5.9 M9.9 M4.4 M
Slightly volatile
Reconciled Depreciation551.1 K281.7 K479 K
Slightly volatile

Kala Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock398.8 K419.8 K26 M
Very volatile
Depreciation631.1 K348.4 K494.3 K
Slightly volatile
Capital Expenditures855.1 K701.5 K639.4 K
Slightly volatile
End Period Cash Flow84.1 M58.5 M59.4 M
Slightly volatile
Stock Based Compensation8.4 M8.6 M5.6 M
Slightly volatile
Begin Period Cash Flow87.2 M81.4 M58.5 M
Slightly volatile
Issuance Of Capital Stock48.1 M44.8 M63.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio16.2817.142.8 K
Slightly volatile
Days Sales Outstanding8757011 K
Slightly volatile
Stock Based Compensation To Revenue1.972.076.4257
Slightly volatile
Capex To Depreciation1.652.322.0155
Slightly volatile
EV To Sales8.559.02.8 K
Slightly volatile
Inventory Turnover0.340.30.3075
Slightly volatile
Days Of Inventory On Hand1.1 K1.3 K1.3 K
Slightly volatile
Payables Turnover0.280.30.5586
Slightly volatile
Sales General And Administrative To Revenue33.4319.2247.8443
Slightly volatile
Research And Ddevelopement To Revenue4.965.2258.9522
Slightly volatile
Capex To Revenue0.08790.09254.4262
Slightly volatile
Cash Per Share22.8624.07114
Very volatile
Days Payables Outstanding1.1 K1.3 K1.4 K
Slightly volatile
Income Quality0.740.60.9116
Pretty Stable
Current Ratio4.195.74.4232
Slightly volatile
Receivables Turnover0.650.691.1738
Pretty Stable
Capex Per Share0.270.291.2556
Slightly volatile
Revenue Per Share3.122.33.8891
Slightly volatile
Interest Debt Per Share14.8115.5953.8409
Pretty Stable
Debt To Assets0.580.750.5738
Very volatile
Operating Cycle1.1 K1.5 K1.6 K
Slightly volatile
Days Of Payables Outstanding1.1 K1.3 K1.4 K
Slightly volatile
Ebt Per Ebit1.131.241.0325
Pretty Stable
Quick Ratio4.15.74.343
Slightly volatile
Net Income Per E B T0.00540.00570.8108
Slightly volatile
Cash Ratio3.645.493.8749
Slightly volatile
Days Of Inventory Outstanding1.1 K1.3 K1.3 K
Slightly volatile
Days Of Sales Outstanding8757011 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.181.0463
Pretty Stable
Fixed Asset Turnover8.848.422.5341
Slightly volatile
Debt Ratio0.580.750.5738
Very volatile
Price Sales Ratio16.2817.142.8 K
Slightly volatile
Asset Turnover0.0280.04030.0311
Slightly volatile
Gross Profit Margin0.590.390.5935
Slightly volatile

Kala Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap63.4 M66.7 M226 M
Slightly volatile
Enterprise Value33.3 M35 M215.7 M
Slightly volatile

Kala Fundamental Market Drivers

Cash And Short Term Investments50.9 M

Kala Upcoming Events

1st of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Kala Pharmaceuticals Financial Statements

Kala Pharmaceuticals stakeholders use historical fundamental indicators, such as Kala Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Kala Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kala Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Kala Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kala Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue967.5 K919.1 K
Cost Of Revenue272.7 K259.1 K
Stock Based Compensation To Revenue 2.07  1.97 
Sales General And Administrative To Revenue 19.22  33.43 
Research And Ddevelopement To Revenue 5.22  4.96 
Capex To Revenue 0.09  0.09 
Revenue Per Share 2.30  3.12 
Ebit Per Revenue(18.81)(19.75)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:
How To Invest In Kala
Details
Is Kala Stock a good investment?
Details
What is Kala Pharmaceuticals' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Kala Pharmaceuticals Correlation against competitors.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.67)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.44)
Return On Equity
(4.31)
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY